Instrument Inactif

Communiqués AAP IMPLANTATE Other OTC

Actions

DE0005066609

Equipement, fournitures et distribution médicale

Cours en clôture Other OTC
- ^USD	-

20/08	Aap Implantate AG annonce la démission de Rubino Di Girolamo de son poste de PDG, effective au 31 décembre 2026	CI
20/08	Aap Implantate AG annonce des changements au sein de sa direction	CI

Communiqués

19/08	Aap Implantate AG: Appointment of new board members and change of CEO at aap Implantate AG	EQ
19/08	Aap Implantate AG: Changes in the Management Board	EQ
18/08	Aap improves profitability in the first half of 2026 and starts the second half of the year with record order intake	EQ
07/05	Aap confirms growth course at the start of 2026 – revenue slightly above previous year, strong momentum in the USA	EQ
30/04	Aap Implantate AG closes financial year 2025 with earnings improvement and provides outlook for 2026	EQ
18/03	Aap successfully completes MDR certification: All existing products approved according to MDR – market access in the EU and CE-relevant markets secured in the long term	EQ
02/02	Further growth in the fourth quarter leads to annual sales of EUR 12.5 million (+2%); Important milestone achieved in antibacterial implants	EQ
07/01	Aap Implantate AG: Deepblue Holding AG, Subscription as part of a capital increase, private placement	EQ
07/01	Aap Implantate AG: Merval AG, Subscription of shares as part of a private placement in connection with a capital increase with exclusion of subscription rights	EQ
06/01	Aap successfully places a 5.7% capital increase from authorised capital at EUR 1.34, excluding subscription rights	EQ
15/12	Aap Implantate : Declaration of Conformity 2025	PU
04/12	Aap Implantate AG: Cash capital increase	EQ
28/10/25	Aap Implantate AG reports strong growth in Q3/2025: +15%	EQ
19/09/25	Aap confirms Rubino Di Girolamo as CEO through the end of 2028; COO Agnieszka Mierzejewska will leave the company at the end of the year	EQ
16/09/25	Aap Implantate AG closes the first half of the year with sales of € 6.2 million; clinical trial nears positive conclusion	EQ
09/09/25	Aap successfully completes human clinical trial for antibacterial surface technology	EQ
01/08/25	Aap Implantate AG: Full admission of all previously unadmitted shares, introduction to stock exchange trading and termination of lock-up agreements	EQ
21/07/25	Aap Implantate AG publishes final audited consolidated financial statements 2024 - confirmation of strong operational improvement	EQ
30/06/25	Aap Implantate AG closes financial year 2024 successfully - positive developments despite challenging environment	EQ
27/06/25	Aap Implantate AG: Company EBITDA for fiscal year 2024 at EUR –0.85 million; postponement of publication of consolidated financial statements	EQ
20/05/25	Aap Implantate : EquityForum 2025	PU
06/05/25	Aap makes a stable start to financial year 2025 - growth in the region with the highest sales EMEA region	EQ
29/04/25	Aap Implantate AG: Postponement of the publication of the annual financial statements and consolidated financial statements for the financial year 2024	EQ
11/04/25	Announcement of an audit order by BaFin	EQ
07/03/25	Aap Implantate : Gender Equality Plan	PU